Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionRNAi therapeutic targeting the HBV genome and uses Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate delivery technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPhase I/II
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat chronic HBV infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today